Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

Up again today: PLE Bid: 174p Offer: 181p Change: 2.5

Dumped this and bought HAWK. Have spent too long waiting for PLE to do something spectacular on the back of the PE product deal, which it hasn't done. Will watch and see how increased revenues affect this in the future, but am on the sidelines for now.

Good luck to holders.

does anyone understand why PLE has moved to FTSE AIM 50??

watch PLE watch MLR

watch PLE - based on??

The fact that a 100% of males, real males that is, not whimpish poofters, want a hard on and only about 75%(BMJ) are able to.

It's about half the sp when you posted David10B - what can you suggest is the reason? . . . . I agree that this appears to be a product men would give their rt arm for (almost), yet now it's at an all-time low - although not that low I'm tempted to buy for "recovery". This slide looks like carelessness - eyes-off-balls etc.

I note that a PhIII-trial is to start for premature ejaculation - something like the hullabaloo over the SP a few years ago....Maybe it's the "Jam tomorrow" problem over again...

EDIT(17Nov08)-16p/19p . . . As I read it, the erectile product is a vacuum-device, whereas I was believing this company was offering a drug-pased product. Doh! - this was 1 only last November!
- Anyone? -

LONDON (ShareCast) - Plethora Solutions (LSE: PLE.L - news) is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler.

Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two phase III trials and is currently awaiting European approval. This approval is expected late in the third quarter or early fourth quarter of 2013.

Importantly, it announced at its interims on December 28th that talks "had commenced with multiple parties to identify a commercial partner to bring PDS502 product to market.

Alexandre believes the stock is "grossly undervalued" and has placed a price target of 15.7p on it, 214% upside on its current 5p price.

Now, as house broker you might perhaps expect him to be keen on the stock but he's positively enthusiastic, while noting that its closing cash balance at the interims was only £0.2m, which means: "We estimate that the company will need to secure further financing."

He's confident that the next 12 months will see the transformation of the company, with the signing of a deal probably before EU approval, as any partner would have to factor in a ramp-up period prior to the product's launch. With that deal would come some sorely needed funds.

With an estimated 30m European men as potential targets for this treatment it may be a compelling investment case.

Alexandre thinks it is: "We believe that PSD502 has the potential to 'go mass market'. Should this transpire, our estimates of the treatment's market potential would be significantly increased. That said, even if the treatment achieves a fraction of this market penetration, Plethora's business would be substantially transformed."

For those of a cautious disposition, who like to invest in well-funded companies, it might be worth holding off until any deal is announced. Yet, the fact that billionaire Jim Mellon, a non-executive director of the company, has been funding the company in return for shares, ought to offer some reassurance for those prepared to gamble on this biotech play.

:-))

Tipped in this weeks share mag. Analysts at Daniel Stewart carry a 15.7p target price in the view strong sales growth and expected launch of the new drug could ''substantially'' transform the business. Management expects European approval for PSD502 in the second half of 2013. The drug has completed two phase III trials and could be launched in the first half of 2014.

I'm in as of earler today...anyone else still in ? any views?

SP up a bit this morning... all looking good so far!

Doing ok for now..just waiting for the good news

Awesome! The good news has arrived... prelude to approval... looking good!

well done sky - in here myself also

a huge market awaits ple now and would suggest this will continue to trend north - many years of r&d in coming to rapid fruition here - great time to buy in & for any that like charts.....

http://www.barchart.com/quotes/stocks/PLE.LS

Looks good gibby and skyhigh.

Positive CHMP Opinion

RNS


RNS Number : 5437O

Plethora Solutions Holdings PLC

20 September 2013










20 September 2013



Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Positive CHMP Opinion

for PSD502 a treatment for premature ejaculation



Plethora Solutions Holdings plc (AIM: PLE) announces that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending European Commission (EC) approval for PSD502 (known in the Marketing Authorisation Application as "Lidocaine Prilocaine Plethora") for the treatment of primary premature ejaculation in adult men.



A CHMP positive opinion is one of the final steps before Marketing Authorisation is granted by the European Commission. The CHMP's positive recommendation will be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union. Plethora anticipates a final decision from the EC shortly, as this usually occurs approximately 60 days after a CHMP recommendation. Plethora anticipates that when approved by the EC PSD502 will be launched in Europe as soon as practicable thereafter.



PSD502 is a treatment for premature ejaculation, comprising a combination of lidocaine and prilocaine in a spray formulation. Clinical studies have demonstrated that PSD502 is effective in treating premature ejaculation with an acceptable safety profile.



Ronald Openshaw, CEO Plethora said:



"Today's announcement by the CHMP is the key opinion the Company has been seeking to obtain European approval. We are delighted by today's news after such a significant period to reach this milestone.



Premature ejaculation is a highly distressing condition for patients and their partners and there remains a significant unmet medical need given the lack of effective products to treat it.



Our efforts are now focussed on achieving a European launch post EC approval and on the US filing with the FDA. The Company's goal is to see PSD502 available internationally to improve the lives of so many couples."





-Ends-

well done dc didn't realise you had these - and thanks - expecting much more here the global market is huge and affects normal peoples every day lives and not some mine or oil field in the middle of some war torn country somewhere

the latest ple personnel addition and other items strongly suggest take over at some point - personally holding out for a 3 figure sp especially after ema rubber stamping (but might sell some at 50p lols)

this is a very good buy in level and be interesting to see what Monday holds as most short term traders already exited Friday - likely they will be back but would suggest their re-buy price should be much higher
looking at the longer term though very good imo
cheers